Alison M. Schram, Olumide B. Gbolahan, Cindy Neuzillet, Dirk Arnold, Antoine Hollebecque, Richard Greil, Mohammed Najeeb Al Hallak Jordi Rodon Ahnert, Kim A. Reiss, Paul F. La Porte, Tormod Kyrre Guren, Carolyn E. Ragsdale, Fiona Garner, Alejandro D. Ricart, Shola Adeyemi, 13 Christoph Springfeld Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: analysis from the phase 2 eNRGy trial , ASCO GI 2026, San Francisco, CA: 2026
Ben Boursi, MD; Zakary L. Kolkey, MD; Kim Anna Reiss, MD; Mark H. O’Hara, MD; William Chapin, MD, MSCE Comparative effectiveness of oxaliplatin or irinotecan rechallenge/reintroduction vs standard third-line therapies in patients with metastatic colorectal cancer , ASCO GI 2026, San Francisco, CA: 2026
Emmanuel S. Antonarakis, Katherine L. Nathanson, Kim A. Reiss, Colin C. Pritchard, Jacob E. Berchuck, Kimberly Johnson, Derek W. Brown, Hanna Tukachinsky CH mutations in 16,812 advanced cancer patients: Overestimation of CH-derived BRCA1/2 variants detected on liquid biopsy (Letter) , Clinical Cancer Research: 2025
Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson Susan M. Domchek, Kim A. Reiss LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes , JCO Precision Oncology: 2025
Susan M. Domchek, Alex Torres, Megan Aaron-Ocko, JoAnn Miller, Phil Seger, Hayley Knollman, Kim Reiss, Payal D. Shah, Matthew Morrow, Jeffrey Skolnik, Robert H. Vonderheide Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with BRCA1/2 mutations , Oral Abstract Session, ASCO 2025, Chicago, IL: 2025
Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes , ASCO 2025, Chicago, IL : 2025
Uri Amit MD MPH PhD, James M Metz MD, John P Plastaras MD PhD, Rohi Gheewala MD, Peter O’Dwyer MD, Ursina Teitelbaum MD, Nevena Damjanov MD, Charles Vollmer MD, Charles J Schneider MD, Major Kenneth Lee IV, MD, PhD, Mark O’Hara MD, Kim A. Reiss MD, Erica L Carpenter PhD, Thomas B Karasic MD, Andre Konski MD, Rosmarie Mick, Paul Wileyto PhD and Edgar Ben-Josef MD A Phase I Dual Dose Escalation Study of Radiation and Nab-paclitaxel in Patients with Unresectable and Borderline Resectable Pancreatic Cancer , Cancer: 2025
Bever KM, Durham JN, Qi H, Azad NS, Laheru D, Fisher GA, Greten TF, Hays J, Krishnamurthy A, Reiss KA, Sanborn R, Wang H, Diaz LA, Le DT 10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors (KEYNOTE-016) , Rapid Oral Abstract Session, ASCO 2025, Chicago, IL : 2025
Kim A. Reiss, Katherine Nathanson, Alexa B. Schrock, Alexander D. Fine, Derek W. Brown, Brennan Decker, Jason Hughes, Chang Xu, Bahar Yilmazel, Rebecca Hodges, Kimberly Johnson, Amaya Gasco, Hanna Tukachinsky BRCA1/2 and PALB2 short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC) , ASCO 2025, Chicago IL: 2025
Kim A. Reiss MD, Kevin C Soares MD, MS, Robert J Trophy MD, PhD, Bishal Gyawali, MD, PhD, FASCO Treatment innovations in pancreatic cancer: putting patient priorities first , ASCO Educational Book: 2025
